T he human genome encodes 13 distinct 5-HT G-proteincoupled receptors (GPCRs). Drugs targeting 5-HT GPCRs are approved treatments for a diverse array of indications, including obesity, migraine headaches, schizophrenia, anxiety and depression 1, 2 . 5-HT receptors also frequently mediate serious drug side effects via unanticipated 'off-target' actions 1, 3 . A notable example is the now-banned appetite suppressant fenfluramine, which exerts its potent anti-obesity actions by activating 5-HT 2C receptors 4 . Fenfluramine was ultimately withdrawn from the market because of a high incidence of drug-induced valvular heart disease (VHD), which occurs as a result of off-target activation by fenfluramine and its active metabolite norfenfluramine at the closely related 5-HT 2B receptor (5-HT 2B R) 5, 6 . Several other medications, including the anti-migraine drugs methysergide and ergotamine 5 , the anti-parkinsonian medications pergolide and cabergoline 7 , and drugs that treat pituitary adenomas, also have potent off-target actions at 5-HT 2B R, and they have also been withdrawn or their use severely restricted because of druginduced VHD 1, 5 . Of note, both the VHD and fibrosis associated with carcinoid syndrome have been linked to 5-HT 2B R activation 8 . Consequently, candidate medications are routinely screened for 5-HT 2B agonist activity before progressing to clinical trials 9, 10 . Not unexpectedly, 5-HT 2B antagonists have been proposed as potential therapeutics for VHD and other fibrotic disorders, including carcinoid syndrome 11 . Thus, understanding the action of drugs at 5-HT 2B R is clearly important for future drug development.
T he human genome encodes 13 distinct 5-HT G-proteincoupled receptors (GPCRs). Drugs targeting 5-HT GPCRs are approved treatments for a diverse array of indications, including obesity, migraine headaches, schizophrenia, anxiety and depression 1, 2 . 5-HT receptors also frequently mediate serious drug side effects via unanticipated 'off-target' actions 1, 3 . A notable example is the now-banned appetite suppressant fenfluramine, which exerts its potent anti-obesity actions by activating 5-HT 2C receptors 4 . Fenfluramine was ultimately withdrawn from the market because of a high incidence of drug-induced valvular heart disease (VHD), which occurs as a result of off-target activation by fenfluramine and its active metabolite norfenfluramine at the closely related 5-HT 2B receptor (5-HT 2B R) 5, 6 . Several other medications, including the anti-migraine drugs methysergide and ergotamine 5 , the anti-parkinsonian medications pergolide and cabergoline 7 , and drugs that treat pituitary adenomas, also have potent off-target actions at 5-HT 2B R, and they have also been withdrawn or their use severely restricted because of druginduced VHD 1, 5 . Of note, both the VHD and fibrosis associated with carcinoid syndrome have been linked to 5-HT 2B R activation 8 . Consequently, candidate medications are routinely screened for 5-HT 2B agonist activity before progressing to clinical trials 9, 10 . Not unexpectedly, 5-HT 2B antagonists have been proposed as potential therapeutics for VHD and other fibrotic disorders, including carcinoid syndrome 11 . Thus, understanding the action of drugs at 5-HT 2B R is clearly important for future drug development.
5-HT 2B R is a member of the 5-HT 2 subfamily of 5-HT receptors, which also includes 5-HT 2A and 5-HT 2C receptors. 5-HT 2B R activation via G q/11 induces phospholipase C activation, inositol phosphate (IP) accumulation, intracellular calcium release and protein kinase C activation 1, 2 . 5-HT 2B R also recruits β -arrestin2 (also known as arrestin-3; encoded by ARRB2 in humans) and downstream effector activation 9, 12, 13 . Drugs such as lysergic acid diethylamide (LSD) and ergotamine (ERG) prefer arrestin recruitment and are considered 'arrestin-biased agonists' 9, 12, 13 . Over the past few years, there has been an explosion in available GPCR structural information, which has provided a molecular understanding of ligand recognition 14 , receptor dynamics and activation 15 , and ligand-mediated biased signaling 16 . To date, structures of three 5-HT receptors have been determined by X-ray crystallography, those of the 5-HT 1B 17, 18 , 5-HT 2B 12 , and 5-HT 2C 19 receptors, all in complex with the VHD-inducing anti-migraine drug ERG. For the 5-HT 2B receptor, LSD-bound and ERG-bound structures are available and reveal that ergot ligands engage a presumed orthosteric binding pocket (OBP), which is likely shared with the endogenous ligand 5-HT 12, 13, 17 . Indeed, ERG and LSD engage regions outside this OBP, which we have termed the extended binding pocket (EBP). The OBP of 5-HT receptors shares certain features with the OBP exemplified by the β 2 -adrenergic receptor (β 2 AR) 20, 21 , and it includes highly conserved and critical ligand contacts between the amine nitrogen of the ligands and a highly conserved aspartate in transmembrane domain 3 (TM3; for example, Asp 3.32 in the Ballesteros-Weinstein numbering scheme 22 ), as well as polar and aromatic contacts in TM5 and TM6, respectively. These interactions are thought to facilitate the stabilization of active 23 and G-protein-bound 24 conformational states. Little is known, however, regarding the 5-HT receptor EBP, which encompasses extracellular portions of TM3 and TM7 and has been proposed as a potential structural feature that may facilitate biased signaling 2 . Support for this hypothesis comes from analysis of the structure of LSD bound to 5-HT 2B R, in which LSD stereo-selectively engages TM3 and TM7 to evoke potent β -arrestin2 recruitment 13 . Additional insights into the mechanisms of biased agonism have recently emerged, revealing a key ligand interaction between LSD and Leu209 in extracellular loop 2 (EL2), which increases ligand residence time at the receptor that contributes to enhanced timedependent β -arrestin2 recruitment 13 . Additionally, both TM5 and the EL2 regions have recently been exploited for biased ligand design at aminergic GPCRs 25 ; it is unclear how biased activation occurs via contact with these regions of the receptor.
A clearer understanding of how ligand interactions with key binding pocket residues lead to the stabilization of active or inactive states will facilitate the design of agonist, biased agonist and antagonist drugs. The available structures are with a single ligand type (either agonist or antagonist). In instances where agonist and antagonist structures are available, the ligand chemotypes are structurally diverse (for example, β 2 AR, adenosine 2A, the μ and κ opioid receptors, and others 16, 26 ). Such limitations make it difficult to leverage existing GPCR structural information for structure-guided drug design.
Here we identified key residues responsible for 5-HT 2B R activation by comparing the binding modes of chemically similar agonists and antagonists at 5-HT 2B R. Notably, we were able to compare the binding mode of methylergonovine with that of its parent antimigraine drug, methysergide, which differs by a single methyl substituent. To illuminate antagonism, we compared the binding mode of the antagonist lisuride to that of the agonist LSD, which differs by only stereochemistry and an additional nitrogen atom. Finally, we elucidate biased signaling and subtype selectivity by clarifying the binding mode of the selective 5-HT 2B R antagonist LY266097. These insights should accelerate the design of safer and more effective medications.
Results

Structural insights into a 5-HT 2B activation mechanism.
Methysergide is rapidly N-demethylated in vivo to methylergonovine, which is the major active metabolite that mediates methysergide's anti-migraine actions in vivo 27 . Unlike methysergide, which is a 5-HT 2B R antagonist, methylergonovine is a potent 5-HT 2B R agonist 6 responsible for methysergide-induced VHD 5 . Because methysergide differs from methylergonovine by a single '-CH 3 ' moiety ( Fig. 1a) , the pair represents a key ligand set to gain insight into the ligand-based structural features responsible for 5-HT 2B R efficacy. Other unsubstituted N(1)-H ligands, such as methylergonovine, LSD and ERG, are G q partial agonists (Fig. 1b) . By contrast, the N(1)-methyl or alkyl ergoline ligands methysergide (Fig. 1b) and LY215840 ( Supplementary Fig. 1a ) are 5-HT 2B R antagonists.
To identify residues critical for methylergonovine's agonism, we obtained the crystal structure of the 5-HT 2B R-methylergonovine complex at a resolution of 2.9 Å (Fig. 1c and Table 1 ). Methylergonovine forms a salt bridge with Asp135 3.32 in the presumed orthosteric site, and the ergoline ring system forms an edge-to-face π -π stack with residues Phe340 6.51 and Phe341 6.52 in TM6-interactions that are commonly observed in aminergic 20, 23 and 5-HT 13, 17, 19 structures. The binding mode of methylergonovine, when compared with those of LSD and ergotamine, bound to 5-HT 2B R revealed a subtly different positioning of the indole N(1)-H toward TM5 residues, with ERG being the deepest toward Ala225 5.46 and LSD being the shallowest toward the backbone of Gly221 5.42 ( Supplementary Fig. 1b ). This differential positioning is likely caused by a rotation around the axis of the ionic interaction between Asp3.32 and the protonated ergoline amine group 13 . Similar to ERG, N(1)-H of methylergonovine points toward residues Ala225
5.46 and Thr140 3.37 ( Fig. 1d and Supplementary Fig. 1c ). Fig. 1d ). Although there was not an optimal angle for a hydrogen bonding between N(1)-H and residue Thr140 3.37 in the 5-HT 2B R-methylergonovine structure ( Supplementary Fig. 1e ), the close distance suggests that at least an electrostatic interaction (van der Waals, vdW) between residue Thr140 3.37 and N(1)-H may occur during activation. Indeed, 5-HT, which also contains an N(1)-H on the indole, displayed weak G q activity at Thr140Ala 3.37 and Thr140Val 3.37 mutants ( Supplementary  Fig. 1f Fig. 1g ). Thus, methylergonovine's interaction with Thr140 3.37 is critical for 5-HT 2B R activation. . Methysergide failed to demonstrate any measurable G q agonist activity with a Thr140Val 3.37 mutant, where it was expected that the valine and N(1)-methyl could form additional vdW interactions to lead to activation (Fig. 2a) . By contrast, methysergide demonstrated potent G q partial agonist activity ( Fig. 2a and Supplementary  Fig. 2a ) with the Ala225Gly 5.46 mutant, which we hypothesized to introduce more bulk tolerance for methysergide's N(1)-methyl-a notion consistent with TM5 engagement appearing to be important for G-protein-dependent agonism 25 .
Structure of a 5-HT
To test this hypothesis, we obtained a structure for the 5-HT 2B R(Ala225Gly 5.46 )-methysergide complex at 3.1-Å resolution (Fig. 2b , Table 1 and Supplementary Fig. 2b,c) . Similar to what was seen in the structure of the 5-HT 2B R-methylergonvine complex, methysergide made conserved contacts with Asp135 created 'space' (for example, bulk tolerance) for the methysergide's N(1)-methyl at TM5 (Fig. 2c) .
To obtain further insights into methysergide's engagement at TM5, we compared the 5-HT 2B R(Ala225Gly 5.46 )-methysergide structure to that of inactive-state β 2 AR bound to the antagonist ICI-118,551 28 . ICI-118,551, like methysergide, also contains a methyl substitution on its core scaffold that appears to sterically 'push' against residue Ser207 5.46 in TM5. Alignment of both structures revealed a 1-2 Å shift in TM5, in which the extracellular side of TM5 moved closer to methysergide in the 5-HT 2B R(Ala225Gly 5.46 )-methysergide structure, whereas ICI-118,551 precluded TM5 movement via its methyl substituent in the β 2 AR-ICI-118,551 structure (Fig. 2d) . Notably, this TM5 shift is also observed in the nanobodystabilized active state of β 2 AR 23 . Alignment of the structure of the β 2 AR-ICI-118,551 complex with that of the nanobody-stabilized active state of β 2 AR revealed that ICI-118,551 precludes this inward TM5 movement via the methyl substituent ( Supplementary Fig. 2d ). Our results thus reveal that residues Thr140 3.37 and Ala225 5.46 are essential for activation.
Structural basis for a 5-HT 2B activation mechanism via the extended binding pocket. We next focused on the role of the EBP in receptor activation. We have previously shown that LSD's diethylamide, which is key for LSD's potent hallucinogenic effects 29 , contacts TM3 and TM7 within the EBP 13 . Furthermore, we found that recognition of LSD in this region is stereo-selective, as LSD's potent agonism was recapitulated by only the (S,S)-azetidide stereoisomer, a conformationally restricted diethylamide stereoisomer of LSD 13 . Less clear, however, is the effect of opposing stereochemistry at the C8 position in antagonist versus agonist recognition. Here we sought to examine other ergoline ligands, such as lisuride, which has the same ergoline core scaffold as LSD yet possesses an (S)-diethylurea ( Fig. 3a) and is a potent 5-HT 2B R antagonist 30 ( Fig. 3b) . To identify the structural basis for lisuride's antagonism, we solved the structure of the 5-HT 2B R-lisuride complex to a resolution of 3.1 Å (Fig. 3c , Table 1 and Supplementary Fig. 3a,b) (Fig. 3c) , exhibited a more contracted binding pocket. This unexpected difference in binding pose likely explains lisuride's lack of agonism at 5-HT 2B R, whereas contact with TM7 residue Leu362 7.35 in the EBP appears essential for LSD's agonism.
To test the hypothesis that ligand contact with TM7 in the EBP facilitates 5-HT 2B R activation, we made substitutions at residue Leu362 7.35 , which is the closest residue in proximity to lisuride's diethylurea in TM7, to facilitate an interaction between lisuride and TM7. Consistent with our hypothesis, substitution of Leu362 7.35 with asparagine (Leu362Asn 7.35 ), which we predicted would result in formation of a hydrogen bond with the backbone of lisuride's diethylurea moiety, led to G q partial agonism (half-maximal effective concentration (EC 50 ) = 395 nM, E max = 41%; Fig. 3d) . We also ) and Ala225 5.46 (A225 5.46 ) in the OBP. e, Methylergonovine G q -mediated calcium flux agonist activity with Thr140Ala 3.37 (red), Thr140Val 3.37 (blue) and Thr140Ser 3.37 (green) mutants (EC 50 = 18 nM; E max = 64%) relative to wild-type (WT) 5-HT 2B R (black; EC 50 = 19 nM; E max = 66%). f, Methylergonovine G q -mediated calcium flux agonist activity in the Ala225Ser 5.46 (red; EC 50 = 15 nM; E max = 58%) and Ala225Gly 5.46 (blue; EC 50 = 12 nM; E max = 55%) mutants relative to wild-type 5-HT 2B R (black; EC 50 = 23 nM; E max = 64%). Data in b, e and f represent the mean ± s.e.m. from n = 3 independent experiments, each performed in triplicate. Source data are available online.
substituted Leu362
7.35 with either phenylalanine (Leu362Phe 7.35 ) or tyrosine (Leu362Tyr 7.35 ), which could facilitate either a hydrophobic-aromatic interaction (phenylalanine or tyrosine) or a hydrogen bond (tyrosine) with the diethylurea of lisuride. With both mutants, lisuride was a potent partial agonist, with EC 50 values as low as 77 nM (Fig. 3d) for the Leu362Phe 7.35 mutant, a potency comparable to that of LSD with wild-type 5-HT 2B R (EC 50 = 40 nM, E max = 82%; E max = % maximum efficacy compared with full agonist). Substitution of Leu362 7.35 with alanine (Leu362Ala 7.35 ) impaired LSD's G q agonist potency by tenfold (EC 50 = 401 nM, E max = 79%; Fig. 3e ), without altering 5-HT 2B R surface expression levels ( Supplementary Fig. 3d ). Taken together, our results showing that LSD and lisuride occupy the OBP in a similar fashion yet exhibit different poses in the EBP indicate that ligand engagement with TM7, specifically with Leu362 7.35 , leads to an auxiliary mechanism of agonist activation via the EBP (Fig. 3f) .
Divergent actions on β-arrestin recruitment by OBP versus EBP mutations.
We previously reported that ergolines, such as ERG and LSD, display a preference for β -arrestin2 recruitment over G qmediated calcium flux at 5-HT 2B R 12 and that LSD's recruitment of β -arrestin2 appears to be time dependent and a product of its slow off-rate from 5-HT 2B R 13 . A key structural motif identified for LSD's potent β -arrestin2 recruitment is extracellular loop 2 (EL2); however, other regions of the binding pocket that lead to β -arrestin2 recruitment at this receptor remain unexplored. Here we examined the roles of the EBP versus OBP regions for 5-HT 2B R β -arrestin2 recruitment.
First, we examined the OBP mutants that were critical for G q activity for methylergonovine and methysergide (at Thr140 3.37 and Ala225 5.46 , respectively). With the Thr140Ala 3.37 mutant, methylergonovine failed to recruit β -arrestin2 (Fig. 4a) , indicating that the Thr140Ala 3.37 substitution disrupts both G q and β -arrestin2 agonism. Similarly, the Ala225Gly 5.46 substitution, which restores methysergide's G q agonism, also restored methysergide's β -arrestin2 recruitment (Fig. 4b) . These results indicate that OBP activation via Thr140 3.37 and Ala225 5.46 leads to equal contributions for G q activation and β -arrestin2 recruitment, as observed for the endogenous ligand 5-HT ( Supplementary Fig. 4a,b) .
Unexpectedly, the EBP Leu362Phe 7.35 substitution, which restored lisuride's G q agonism, did not restore lisuride's β -arrestin recruitment agonism (Fig. 4c) . Although the Leu362Phe 7.35 substitution did not affect LSD's G q agonism, it abolished LSD's β -arrestin recruitment (Fig. 4d) . Notably, impairment of β -arrestin2 recruitment by substitution at Leu362 7.35 appeared to be dependent on the type of substitution-Leu362Phe 7.35 showed the weakest recruitment for β -arrestin with some restoration by Leu362Tyr 7.35 ( Supplementary Fig. 4c ). Further analysis of the Leu362Phe 7.35 mutant revealed no deficits in G q function as assessed by PI hydrolysis ( Supplementary  Fig. 4d ) or G q/γ1 dissociation, measured by bioluminescence resonance energy transfer (BRET; Supplementary Fig. 4e ). By contrast, the Leu362Phe 7.35 substitution attenuated LSD's time-dependent recruitment of β -arrestin ( Supplementary Fig. 4f ), as observed previously for the EL2 Leu209Ala substitution 13 . Accordingly, we directly measured LSD's dissociation rate with the Leu362Phe 7.35 mutant, observing a > 10-fold faster dissociation rate than for wild-type 5-HT 2B R (Fig. 4e) . Thus, the Leu362Phe 7.35 substitution decreases β -arrestin2 recruitment by accelerating dissociation, thereby contributing to β -arrestin2 recruitment. Taken together, ligand recognition in the OBP results in equivalent G q and β -arrestin2 activity, whereas ligand recognition in the EBP, specifically at TM7, results in either G q or β -arrestin2 recruitment activity and divergent effects on ligand bias (Fig. 4f) .
Structure of 5-HT 2B R-LY266097 reveals TM7 as a trigger for biased signaling. Finally, we explored non-ergoline antagonists with distinct scaffolds to determine whether they displayed similar binding modes that were shared with other 5-HT 2B R antagonists. Although lisuride is a 5-HT 2B R antagonist, it lacks selectivity for 5-HT 2B R, as is commonly observed for many ergolines 19 . LY266097, however, is a purported selective 5-HT 2B R antagonist 31 that contains a distinct tetrahydro-β -carboline pharmacophore, and determining the binding mode of LY266097 could illuminate novel structural determinants of 5-HT 2B R selectivity.
Accordingly, we crystallized LY266097 in a BRIL-fused 5-HT 2B R (BRIL; thermostabilized apocytochrome b562RIL) and solved the 5-HT 2B R-LY266097 structure at 3.2-Å resolution (Fig. 5a , Table 1 and Supplementary Fig. 5a,b) . Analysis of LY266097's binding pose revealed that the tetrahydro-β -carboline core scaffold was oriented in the OBP with the charged nitrogen engaging Asp135 3.32 in TM3 and the tetrahydro-β -carboline core engaging residues Phe340 6.51 and Phe341
6.52 in a π -π aromatic stack. Unexpectedly, when we compared the binding modes of LY266097 and lisuride in the EBP, we observed that LY266097's 2-chloro-3,4-dimethoxybenzyl substituent was oriented much closer to TM7 than that of lisuride (Fig. 5b,c) . On the basis of our previous finding that TM7 appears to be important for biased agonism, we hypothesized that LY266097 should show preference for either G q or β -arrestin2 activity. We found LY266097 to be a modest G q partial agonism without detectable β -arrestin2 activity (Fig. 5d ) and confirmed LY266097's G q partial agonism in an additional assay of G q function via PI hydrolysis (Supplementary Fig. 5c ). We also tested LY266097 in an orthologonal β -arrestin2 recruitment assay using BRET, which measured β -arrestin2 recruitment in real time monitored across specific time points. At no tested time point did LY266097 display β -arrestin2 recruitment ( Supplementary Fig. 5d) ; instead, it displayed potent β -arrestin2 antagonism (Supplementary Fig. 5e ). These results indicate that LY266097 has a bias toward G q .
On the basis of our previous results with lisuride and the Leu362Phe 7.35 mutant, we hypothesized that the extent of G q agonism by LY266097 is determined by ligand contact between 2-chloro-3,4-dimethoxybenzyl and Leu362 7.35 . To confirm that LY266097's contact with TM7 resulted in selective G q activation, we tested LY266097 with the Leu362Phe 7.35 mutant, which was previously found to restore lisuride's G q agonist activity. As expected, LY266097's G q agonist activity was abolished with the Leu362Phe 7.35 mutant (Fig. 5e) , suggesting that the bulkiness of the phenylalanine in the Leu362Phe 7.35 mutant sterically clashed with the 2-chloro-3,4-dimethoxybenzyl moiety, resulting in a lack of agonism. To provide additional evidence that TM7 influences activation via strict steric requirements, we synthesized analogs of LY266097 that lacked either a 2-chloro or a 3,4-dimethoxy substituent on the benzyl moiety, which would be expected to show less TM7 interaction. We found a substituent-dependent decrease in G q -mediated agonist potency, with the unsubstituted benzyl analog showing no detectible G q agonist activity, indicating that the substitution pattern to LY266097's scaffold conferred G q agonism (Fig. 5f) .
Similar to methysergide, LY266097 contains a methyl substituent on the tetrahydro-β -carboline scaffold that appears to 'push' on TM5 at position Gly221 5.42 ( Fig. 5g) , a key residue implicated in conferring 5-HT 2 subtype selectivity 19 . To determine whether LY266097's methyl substituent was in part responsible for G q partial agonism, we synthesized a des-methyl analog of LY266097 and found that it was nearly a full agonist (EC 50 = 20 nM; E max = 93%; Fig. 5h ). These results suggest that the methyl substituent on LY266097 and its interaction with TM5 impair agonism.
Discussion
Here leveraged by four new 5-HT 2B crystal structures, including the structure of a mutant receptor (Ala225Gly 5.46 ) designed to switch a ligand's efficacy, we provide a comprehensive structural analysis of ligand-specific contacts that lead to GPCR activation. Notably, this study not only identifies mechanisms of 5-HT GPCR activation via the orthosteric site, but also identifies important determinants of β -arrestin recruitment via the EBP, thereby illuminating determinants of ligand bias that could apply to other GPCRs. Our results with the 5-HT 2B R-methylergonovine and 5-HT 2B R(Ala225Gly 5.46 )-methysergide structures illuminate an orthosteric activation mechanism that occurs via ligand engagement with residues Thr140 3.37 and Ala225 5.46 . Although residue Ala225 5.46 has been implicated as an important determinant of activation in β -adrenergic receptors 21, 32 , the role of the highly conserved Thr140 3.37 residue is less understood. In fact, crystallographic evidence that shows direct ligand engagement with residue Thr140 3.37 in TM3 is scarce. In rhodopsin, however, the β -ionone ring of retinal, which is critical for receptor activation, is directly engaged with the Glu122 3.37 residue. Retinal interaction with Glu122 3.37 has been posited to lead to disruption of a hydrogen bond between Glu122 3.37 and His211 5.46 , which causes an inward rotation of TM5, transducing disruption of the ionic lock between the intracellular portions of TM3 and TM6 33 .
Although here ligand engagement with Thr140
3.37 appears to involve either a hydrogen bond or an electrostatic interaction, it remains to be seen whether this ligand contact occurs frequently with other ligands or whether its role is more indirect (and in concert with residue Ala225 5.46 ) in the activation process, especially considering that residue Thr140 3.37 is highly conserved across aminergic GPCRs. Our results do emphasize that ligand engagement with residue Ala225 5.46 and TM5 movement is important for an orthosteric mechanism of class A aminergic GPCRs-both regions highly conserved in aminergic GPCRs that we have previously exploited to design biased ligands 25 . To our knowledge, our results with the 5-HT 2B R-lisuride structure are the first to reveal a mechanism of activation that occurs ). Data represent the percentage specific binding, indicating the mean ± s.e.m. from n = 3 independent experiments, performed in duplicate. f, Schematic comparing the location of the EBP residues Leu209 EL2 and Leu362 7.35 (purple), which contribute to either G q or β -arrestin2 recruitment preference, to the location of OBP residues Thr140 3.37 and Ala225 5.46 (green), which have equal contributions to G q activity and β -arrestin2 recruitment. Source data for the graphs are available online.
via the EBP, specifically via ligand contact with TM7 at residue Leu362 7.35 . This extended binding region of the receptor is less conserved, allowing for ligand-specific engagement of non-conserved residues, and it likely explains the diverse pharmacological action that results from ligand-specific substituents that project from the core scaffold, as in the case of LSD, where the diethylamide projects away from the core ergoline scaffold. Of note, the same residues, Trp131 3.28 , Leu132
3.29 and Leu362 7.35 , which are also involved in recognition of LSD's diethylamide and lisuride's diethylurea, compose part of the allosteric site of muscarinic receptors 34 . This suggests that ergoline ligands, such as LSD, access a potential allosteric site, leading to a diverse pharmacological profile (for example, antagonism or biased agonism). However, it remains to be seen whether bona fide allosteric modulators can selectively target the EBP of 5-HT receptors, leading to bias.
Further study of the structural dynamics that lead to activation, either via the OBP or EPB, is needed to clarify trigger motifs (for example, NPxxY, P-I-F, DRY) involved in either balanced or biased activation. Although BRIL-fusion 5-HT 2B R structures adopt an 'active intermediate' state, more 'active-like' 5-HT 2B R structures will , whereas lisuride's (S)-diethylurea is further away, at 6.3 Å from Leu362 7.35 . d, Profiling of LY266097 for ligand bias showing G q partial agonist activity (red closed circles; EC 50 = 37 nM; E max = 62%) and partial antagonist activity (red open circles; IC 50 = 78 nM), but no β -arrestin2 recruitment activity (blue). e, LY266097 G q -mediated calcium flux activity comparing the Leu362Phe 7.35 mutant (red) to wild-type 5-HT 2B R (black; EC 50 = 41 nM; E max = 54%). f, G q -mediated calcium flux activity of benzyl-substituted LY266097 analogs 3,4-diMeOBenzyl (blue; EC 50 = 24 nM; E max = 46%), 2-Clbenzyl (orange; EC 50 = 35 nM; E max = 28%) and unsubstituted benzyl (red). g, 5-HT 2B R-LY266097 structure showing that the methyl substituent on the tetrahydro-β -carboline scaffold interacts with the 5-HT 2 -specific residue Gly221 5.42 . h, G q -mediated calcium flux activity of a des-methyl LY266097 analog (purple; EC 50 = 20 nM; E max = 93%) results in nearly full agonist activity as compared to 5-HT (black; EC 50 = 0.7 nM) or LY266097 (red; EC 50 = 41 nM; E max = 54%). Data in d-f and h represent the mean ± s.e.m. from n = 3 independent experiments, performed in triplicate. Source data are available online.
likely shed light on key trigger motifs involved in G protein versus β -arrestin2 recruitment. Indeed, current inactive-state structures of 5-HT 2C 19 and 5-HT 1B
18
, which have both been co-crystallized with inverse agonists, implicate the conserved P-I-F trigger as a motif essential for inactivation and biased signaling.
In our study here, Leu362 7.35 in TM7 appears to be an important determinant of preference for G protein or β -arrestin2 recruitment, as was also implied for κ -opioid receptor biased signaling and for other GPCRs 35, 36, 37 . In the case of LY266097, which appears to make no specific vdW or hydrogen bond contacts with residues in TM7, our results with Leu362 7.35 mutants suggest that ligand engagement with TM7 may operate under strict steric constraints, as was similarly observed in the 5-HT 2B R Ala225Gly 5.46 -methysergide structure. Notably, hydrophobic contact with Leu362 7.35 , as in the case of LSD, leads to enhanced ligand residence time, and contributions from both TM7 and EL2 serve to stabilize ligand residence time. In fact, increased ligand residence time has been shown to lead to increased β -arrestin2 recruitment over time 13 , and it appears to be a hallmark of β -arrestin-biased ligands at aminergic GPCRs 25 . Further study, however, is required to illuminate subsequent signaling after arrestin recruitment, especially as it relates to G protein dependence, as shown in one recent study 8 . Nevertheless, our study illuminates that receptor recognition of small substitutions to core ligand scaffolds directly modulates G protein versus β -arrestin recruitment preferences 37 . Identification of critical residue(s) for 5-HT 2B R agonist versus antagonist recognition and encoding of efficacy is important for drug design strategies, which aim to avoid 5-HT 2B R activation and VHD. On the basis of our previous structural and functional studies with 5-HT 2B R, it is clear that 5-HT 2B R represents an attractive receptor template to clarify the structural features necessary for biased signaling as they apply to other class A GPCRs. Insights into the structural basis of agonist versus antagonist action at GPCRs are essential for the design of safer and more effective medications.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41594-018-0116-7.
Generation of 5-HT 2B receptor constructs. Constructs encoding 5-HT 2B R for the generation of crystals were based on previously published 5-HT 2B R constructs in which thermostabilized apocytochrome b 562 RIL (M7W, H102I, R106L) from Escherichia coli-referred to as BRIL-was fused to intracellular loop 3 (ICL3) 38, 39 of the receptor 12, 13 . The 5-HT 2B R-LY266097 and 5-HT 2B R-lisuride complexes were crystallized using a previously crystallized construct (h5-HT 2B R-BRIL-1) that lacked N-terminal residues 1-35 and C-terminal residues 406-481, contained a thermostabilizing Met144Trp 3.41 substitution 40 and possessed residues Ala1 to Leu106 of BRIL in place of receptor residues Tyr249 to Val313 of ICL3 38, 39 . The 5-HT 2B R-methylergonovine complex was crystallized by using a different previously crystallized construct 13 (h5-HT 2B R-BRIL-2) that included Val313 but that was otherwise identical to h5-HT 2B R-BRIL-1. The 5-HT 2B R(Ala225Gly 5.46 )-methysergide complex (h5-HT 2B R-BRIL-3) was generated by QuikChange (Agilent) PCR, mutating the sequence for Ala225 5.46 to glycine in the h5-HT 2B R-BRIL-2 construct. All constructs also contained a hemagglutinin (HA) signal sequence followed by a FLAG tag at the N terminus and a PreScission protease site followed by a 10 × histidine tag (His tag) at the C terminus to enable purification by immobilized metal affinity chromatography.
Expression and purification of the 5-HT 2B constructs. High-titer recombinant baculovirus (> 10 9 viral particles/ml) was generated using the Bac-to-Bac Baculovirus Expression System (Invitrogen). Recombinant baculovirus was obtained by transfecting ~5 µ g of recombinant bacmid into 5 × 10 5 settled Spodoptera frugiperda (Sf9) cells (Expression Systems) in a 12-well plate (Corning) using 3 µ l of Cellfectin II Reagent (Invitrogen). After 5-12 h, medium was exchanged for 1 ml of Sf-900 II SFM medium (Invitrogen), and the plates were incubated for 4-6 d at 27 °C. P0 viral stock was harvested as the supernatant and used to generate high-titer baculovirus stock by infection of 40-1,000 ml of 2 × 10 6 Sf9 cells/ml and incubation for 3 d. Viral titers were determined by flow cytometry analysis of cells that were stained with phycoerythrin (PE)-conjugated gp64 antibody (Expression Systems) 38 . Expression of 5-HT 2B R was carried out by infection of Sf9 cells at a cell density of 2 × 10 6 to 3 × 10 6 cells/ml in ESF921 medium (Expression Systems) with P1 virus at a multiplicity of infection (MOI) of 3-5. Cells were harvested by centrifugation at 48 h after infection, washed in PBS and stored at -80 °C until use. Cells were disrupted by thawing frozen cell pellets in a hypotonic buffer (10 mM HEPES, 10 mM MgCl 2 , 20 mM KCl, pH 7.5) containing protease inhibitors (500 µ M AEBSF, 1 µ M E-64, 1 µ M leupeptin, 150 nM aprotinin). Membranes were purified by repeated centrifugation in a high-osmotic buffer (containing 10 mM HEPES, 1 M NaCl, 10 mM MgCl 2 , 20 mM KCl, pH 7.5) to remove soluble and membrane-associated proteins. Purified membranes were directly flash-frozen in liquid nitrogen and stored at -80 °C until protein purification. Purified membranes were resuspended in a buffer containing 10 mM HEPES, 10 mM MgCl 2 , 20 mM KCl, 150 mM NaCl (pH 7.5) and protease inhibitors and were incubated for 1 h at room temperature with 50 µ M methylergonovine (Sigma, M2776), methysergide (Sigma, M137), lisuride (Tocris, 4052) or LY266097 (Tocris, 4081). After a 30-min incubation in the presence of 2 mg/ml iodoacetamide (Sigma), membranes were solubilized in 10 mM HEPES, 150 mM NaCl, pH 7.5, 1% (wt/vol) n-dodecyl-β -d-maltopyranoside (DDM, Anatrace), 0.2% (wt/vol) cholesteryl hemisuccinate (CHS, Sigma), 25 µ M of the indicated complex ligand and protease inhibitors for 2 h at 4 °C. Unsolubilized material was removed by centrifugation at 150,000g for 30 min, and 15 mM imidazole was added to the supernatant. Proteins were bound to TALON IMAC resin (Clontech) overnight at 4 °C using approximately 750 µ l of resin for protein purified from 2 liters of cells. The resin was then washed with 10 column volumes (CVs) of Wash Buffer I (50 mM HEPES, 800 mM NaCl, pH 7.5, 0.1% (wt/vol) DDM, 0.02% (wt/vol) CHS, 20 mM imidazole, 10% (vol/vol) glycerol and 20 µ M of the indicated complexing ligand), followed by 10 CVs of Wash Buffer II (25 mM HEPES, 150 mM NaCl, pH 7.5, 0.05% (wt/vol) DDM, 0.01% (wt/vol) CHS, 10% (vol/vol) glycerol and 20 µ M of the indicated complexing ligand). Proteins were eluted in 2.5 CVs of Wash Buffer II + 250 mM imidazole and concentrated in a Vivaspin 20 concentrator with a molecular weight cutoff of 100 kDa (Sartorius Stedim) to 500 µ l; imidazole was removed by desalting the protein over PD MiniTrap G-25 columns (GE Healthcare). The C-terminal 10 × His tag was removed by addition of Histagged PreScission protease (GenScript) and incubation overnight at 4 °C. Protease, cleaved His tag and uncleaved protein were removed by passing the suspension through equilibrated TALON IMAC resin (Clontech) and collecting the flowthrough. 5-HT 2B R-ligand complexes were then concentrated to ~30 mg/ml using a Vivaspin 500 centrifuge concentrator with a molecular weight cutoff of 100 kDa (Sartorius Stedim). Protein purity and monodispersity were tested by analytical size-exclusion chromatography.
Lipidic cubic phase crystallization. 5-HT 2B R-ligand complexes were reconstituted into lipidic cubic phase (LCP) by mixing protein and a monoolein:cholesterol mixture at a ratio of 40%:54%:6% by using the twin-syringe method 5 . Crystallization was done on 96-well glass sandwich plates (Marienfeld) in 50-nl LCP drops that were dispensed from a 10-µ l gas-tight pipette (Hamilton) using a handheld dispenser (Art Robbins Instruments) and overlaid with 1 µ l of precipitant solution. After optimization, crystals were obtained in 100 mM Tris-HCl pH 8.0, 100 mM sodium formate and 30% (vol/vol) polyethylene glycol 400 (PEG400) for h5-HT 2B R-BRIL-1-LY266097; 100 mM Tris-HCl pH 7.4-7.7, 30-50 mM ammonium tartrate dibasic and 30% (vol/vol) PEG400 for h5-HT 2B R-BRIL-1-lisuride; 100 mM Tris-HCl pH 7.2-8.0, 170-190 mM potassium phosphate monobasic and 30% (vol/vol) PEG400 for h5-HT 2B R-BRIL-2-methylergonovine; and 100 mM Tris-HCl pH 7.3-7.5, 40-100 mM MgCl 2 and 30% (vol/vol) PEG400 for h5-HT 2B R(Ala225Gly 5.46 )-BRIL-3-methysergide. All crystals grew to a maximum size of ~70 µ m × 30 µ m × 20 µ m within 3 d and were harvested directly from the LCP matrix using MiTeGen micromounts before flash-freezing and storage in liquid nitrogen.
Data collection, structure solution and refinement. X-ray data were collected at the 23ID-B and 23ID-D beamline (GM/CA CAT) at the Advanced Photon Source (Argonne, IL, USA), using a 10-µ m minibeam at a wavelength of 1.0330 Å and either a MarMosaic 300 charge-coupled detector (CCD) or an Eiger-16m detector (Dectris). Diffraction data were collected by exposing the crystals for 1-3 s to unattenuated beam using primary oscillation. Full datasets for each complex were assembled from several crystals owing to the rapid onset of radiation decay at such high doses. Data were indexed, integrated, scaled and merged using HKL3000 41 , and initial phases were obtained by molecular replacement in PHASER 42 using the 5-HT 2B R coordinates from PDB 4IB4 with the ligand, extracellular loops and orthosteric residues removed. Refinement was performed with PHENIX 43 and REFMAC and included extensive use of simulated annealing to remove model bias. Density was manually examined, and coordinates were rebuilt in COOT G q -mediated calcium flux FLIPR assays. Stable cell lines were generated for wild-type 5-HT 2B R and all of the 5-HT 2B R mutants using the Flp-In 293 T-Rex Tetracycline-inducible system (Invitrogen, mycoplasma-free). Cell lines were maintained in DMEM containing 10% FBS, 10 µ g/ml blasticidin (Invivogen) and 100 µ g/ml hygromycin B (KSE Scientific). The day before the FLIPR assay, tetracycline-induced cells were seeded into 384-well poly-(l-lysine)-coated black plates at a density of 10,000 cells/well in DMEM containing 1% dialyzed FBS. On the day of the assay, the cells were incubated with Fluo-4 Direct dye (Invitrogen, 20 µ l/well) for 1 h at 37 °C, which was reconstituted in drug buffer (20 mM HEPES-buffered Hank's Buffered Salt Solution (HBSS), pH 7.4) containing 2.5 mM probenecid. After dye loading, cells were allowed to equilibrate to room temperature for 15 min and were then placed in a FLIPR TETRA fluorescence imaging plate reader (Molecular Dynamics). Drug dilutions were prepared at 5 × final concentration in drug buffer (20 mM HEPES-buffered HBSS, pH 7.4) containing a final concentration of 0.1% BSA and 0.01% ascorbic acid. Drug dilutions were aliquotted into 384-well plastic plates and placed in the FLIPR TETRA for drug stimulation. The drug solutions used for the FLIPR assay were exactly the same as those used for the Tango assay. The FLIPR TETRA was programmed to read baseline fluorescence for 10 s (1 read/s), and afterward 5 µ l of drug/well was added and read for a total of 3 min (1 read/s). Fluorescence in each well was normalized to the average of the first ten reads for baseline fluorescence, and then the maximum fold increase was determined and calculated as fold change relative to basal levels (fold-over-basal). Fold-over-basal was plotted as a function of drug concentration, and data were normalized to percent 5-HT stimulation. Data were plotted, and nonlinear regression was performed using 'log(agonist) versus response' in GraphPad Prism 5.0 to yield E max and EC 50 parameter estimates. β-arrestin2 recruitment Tango assays. Measurement of β -rrrestin2 recruitment at 5-HT 2B R and its mutants used constructs that contained a TEV protease cleavage site and the tetracycline transactivator (tTA) fused to the C terminus of the receptor. Assays were designed and performed as previously described 45 . HTLA cells expressing TEV-fused β -arrestin2 (derived from HEK cells and kindly provided by R. Axel) were grown and maintained in DMEM containing 10% FBS, 5 µ g/ml puromycin and 100 µ g/ml hygromycin B. On the day of transfection, medium was removed from the HTLA cells, the cells were washed with PBS, and DMEM containing 10% dialyzed FBS and no antibiotics was added. After at least 1 h, the cells were transfected with the 5-HT 2B R-or mutant-encoding constructs using a calcium-phosphate precipitation method 46 . After at least 24 h, medium was decanted, and the cells were washed with PBS and detached using trypsin. Cells were collected via centrifugation, resuspended in DMEM containing 1% dialyzed FBS and plated into poly-(l-lysine)-coated 384-well white clear-bottom cell culture plates at a density of 7,000-10,000 cells/well in a total of 40 µ l. The cells were incubated at 37 °C and 5% CO 2 for at least 6 h before receiving drug stimulation. Drug solutions were prepared in drug buffer (20 mM HEPES-buffered HBSS, pH 7.4) containing 0.1% BSA and 0.01% ascorbic acid (final concentrations). Drug stimulation was performed using the FLIPR TETRA system by dispensing 10 µ l/well. 
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